Validation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the rotterdam ischemic heart disease and stroke computer simulation (RISC) model

被引:9
作者
van Kempen, Bob J. H. [1 ,2 ]
Ferket, Bart S. [1 ,2 ]
Hofman, Albert [1 ]
Steyerberg, Ewout W. [3 ]
Colkesen, Ersen B. [6 ]
Boekholdt, S. Matthijs [5 ]
Wareham, Nicholas J. [7 ]
Khaw, Kay-Tee [8 ]
Hunink, M. G. Myriam [1 ,2 ,4 ]
机构
[1] Erasmus MC, Dept Epidemiol, NL-3015 GE Rotterdam, Netherlands
[2] Erasmus MC, Dept Radiol, NL-3015 GE Rotterdam, Netherlands
[3] Erasmus MC, Dept Publ Hlth, NL-3015 GE Rotterdam, Netherlands
[4] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA
[5] Amsterdam Med Ctr, Dept Cardiol, NL-1150 AZ Amsterdam, Netherlands
[6] Antonius Hosp, Dept Cardiol, NL-3435 CM Nieuwegein, Netherlands
[7] MRC, Epidemiol Unit, Cambridge CB2 0QQ, England
[8] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB2 0SR, England
来源
BMC MEDICINE | 2012年 / 10卷
基金
英国医学研究理事会;
关键词
Cardiovascular disease prevention; Simulation modeling; Model validation; MEDICAL DECISION-MODELS; PATIENT HETEROGENEITY; PRIMARY PREVENTION; COST-EFFECTIVENESS; STATIN TREATMENT; DIABETES MODEL; MARKOV MODEL; CORONARY; MORTALITY; UNCERTAINTY;
D O I
10.1186/1741-7015-10-158
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We developed a Monte Carlo Markov model designed to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD. Internal, predictive, and external validity of the model have not yet been established. Methods: The Rotterdam Ischemic Heart Disease and Stroke Computer Simulation (RISC) model was developed using data covering 5 years of follow-up from the Rotterdam Study. To prove 1) internal and 2) predictive validity, the incidences of coronary heart disease (CHD), stroke, CVD death, and non-CVD death simulated by the model over a 13-year period were compared with those recorded for 3,478 participants in the Rotterdam Study with at least 13 years of follow-up. 3) External validity was verified using 10 years of follow-up data from the European Prospective Investigation of Cancer (EPIC)-Norfolk study of 25,492 participants, for whom CVD and non-CVD mortality was compared. Results: At year 5, the observed incidences (with simulated incidences in brackets) of CHD, stroke, and CVD and non-CVD mortality for the 3,478 Rotterdam Study participants were 5.30% (4.68%), 3.60% (3.23%), 4.70% (4.80%), and 7.50% (7.96%), respectively. At year 13, these percentages were 10.60% (10.91%), 9.90% (9.13%), 14.20% (15.12%), and 24.30% (23.42%). After recalibrating the model for the EPIC-Norfolk population, the 10-year observed (simulated) incidences of CVD and non-CVD mortality were 3.70% (4.95%) and 6.50% (6.29%). All observed incidences fell well within the 95% credibility intervals of the simulated incidences. Conclusions: We have confirmed the internal, predictive, and external validity of the RISC model. These findings provide a basis for analyzing the effects of modifying cardiovascular disease risk factors on the burden of CVD with the RISC model.
引用
收藏
页数:13
相关论文
共 34 条
  • [1] Projected Effect of Dietary Salt Reductions on Future Cardiovascular Disease
    Bibbins-Domingo, Kirsten
    Chertow, Glenn M.
    Coxson, Pamela G.
    Moran, Andrew
    Lightwood, James M.
    Pletcher, Mark J.
    Goldman, Lee
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (07) : 590 - 599
  • [2] Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994
    Capewell, S
    Morrison, CE
    McMurray, JJ
    [J]. HEART, 1999, 81 (04) : 380 - 386
  • [3] Validation of the Framingham Coronary Heart Disease prediction scores - Results of a multiple ethnic groups investigation
    D'Agostino, RB
    Grundy, S
    Sullivan, LM
    Wilson, P
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (02): : 180 - 187
  • [4] Day N, 1999, BRIT J CANCER, V80, P95
  • [5] Validation of the archimedes diabetes model
    Eddy, DM
    Schlessinger, L
    [J]. DIABETES CARE, 2003, 26 (11) : 3102 - 3110
  • [6] Fowkes FGR, 2008, JAMA-J AM MED ASSOC, V300, P197, DOI 10.1001/jama.300.2.197
  • [7] Empirically Evaluating Decision-Analytic Models
    Goldhaber-Fiebert, Jeremy D.
    Stout, Natasha K.
    Goldie, Sue J.
    [J]. VALUE IN HEALTH, 2010, 13 (05) : 667 - 674
  • [8] GROVER SA, 1992, JAMA-J AM MED ASSOC, V267, P816
  • [9] GUNNINGSCHEPERS L, 1989, HEALTH POLICY, V12, P1
  • [10] THE COST-EFFECTIVENESS OF HMG-COA REDUCTASE INHIBITORS TO PREVENT CORONARY HEART-DISEASE - ESTIMATING THE BENEFITS OF INCREASING HDL-C
    HAMILTON, VH
    RACICOT, FE
    ZOWALL, H
    COUPAL, L
    GROVER, SA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (13): : 1032 - 1038